![Computer work timer](https://loka.nahovitsyn.com/173.jpg)
Thomas Arendt at the University of Leipzig that he has completed enrollment and is currently analyzing data from 20 subjects participating in Part 2 of the LymPro vs. The Company has received communication from Dr.
Call quest diagnostics online results trial#
Commissiong continued, “We currently have collected 40 breast cancer patient samples from an ongoing government-sponsored clinical trial in Mexico as we prepare for the CLIA re-validation of our Videssa breast cancer blood test launch in 2023 for women who 1) are below 42 and ineligible for mammograms, 2) have previously had breast cancer and want to monitor for potential recurrence, and 3) with dense breasts for whom mammograms yield inconclusive results, as well as file for regulatory authorization for Videssa in key jurisdictions outside the United States. Aligning our Tollovid marketing around clinically validated, relevant COVID & Long COVID biomarker changes should further separate it from other supplements in the marketplace with data.” The launch of our Long COVID testing partnership with Amerimmune Diagnostics now allows us to collect blood samples through their national Quest Diagnostics partnership, with the expectation that we will ultimately be able to add immune system integrity biomarker data to the SARS-CoV-2 neutralizing antibody data we have reported seeing for Tollovid. We have recently added MonkeyPox PCR testing to our menu and have started early commercialization efforts. Goix has had significant success selling into throughout his career, target clients are healthcare providers who have few genetic testing alternatives available in their markets that can deliver fast turnaround time (TAT) like Provista. With the initial PCR launch focusing on skilled nursing facilities in underserved, geographically remote communities outside major metropolitan areas in which Dr. “Under his guidance, we are now prepared to launch Urinary Track Infection (UTI), Wound, Respiratory, Gastrointestinal and Sexually Transmitted Infection PCR panels for the US market in September. Philippe Goix,” said Gerald Commissiong, President & CEO of Todos Medical. “While the second quarter marked a period of transition for Provista, it made significant progress in preparing to further expand its revenue base beyond SARS-Co-V-2 PCR testing as we head into the second half of the year under the leadership of our new Chief Commercial Officer, Dr. Given that Long COVID patients have no approved therapeutic options and rely almost exclusively on supplementation, we believe that Tollovid has a tremendous opportunity to become the supplement of choice for Long COVID.” Sales of our Tollovid product also became material and more consistent in the second quarter as we identified Long COVID patients as a niche market and looked to initiate our sales and marketing efforts towards the Long COVID community and generate data that could serve as the basis marketing materials and prospective clinicals studies based upon data. “We were able to complete that transition and have seen month-over-month growth in testing revenues at Provista throughout the second quarter of 2022, culminating with over $800,000 in revenue for the month of June 2022. “Todos’ diagnostics focus for the first half of 2022 was really about completing the transition from primarily being a company that generates revenues by selling materials and supplies into 3rd party high-complexity CLIA labs through our Corona Diagnostics business to primarily generating revenues through the sales of testing services through our own Provista Diagnostics CLIA/CAP PCR Testing lab,” said Daniel Hirsch, Chief Financial Officer of Todos Medical. Time: Tuesday, August 22nd, 2022 at 8:30am ET
Call quest diagnostics online results update#
Todos Medical Business Update Conference Call:
![call quest diagnostics online results call quest diagnostics online results](https://mma.prnewswire.com/media/974355/Quest_Lab_Stewardship_powered_by_hc1.jpg)
![call quest diagnostics online results call quest diagnostics online results](https://i0.wp.com/www.drd4sevenr.com/wp-content/uploads/2020/06/Quest-D-Sign-1200.jpg)
(OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today reported financial results for the second quarter of 2022 ended June 30, 2022, and announced a business update conference call to be held on Tuesday, August 23, 2022, at 8:30am ET. 22, 2022 (GLOBE NEWSWIRE) - via NewMediaWire – Todos Medical, Ltd.
![Computer work timer](https://loka.nahovitsyn.com/173.jpg)